Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph P Colgan

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
British Journal of Haematology|February 25, 2012
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphomaLuis F Porrata, Kay Ristow, Thomas M Habermann, et al.
British Journal of Haematology|April 17, 2007
Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomasDeepti Behl, Kay Ristow, Svetomir N Markovic, et al.
American Journal of Hematology|March 16, 2010
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphomaPatrick B Johnston, David J Inwards, Joseph P Colgan, et al.
Ophthalmology|December 20, 2005
Natural killer/T-cell lymphoma with ocular and adnexal involvementJohn J Woog, Yoon Duck Kim, R Patrick Yeatts, et al.
Leukemia & Lymphoma|November 22, 2011
The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphomaRyan A Wilcox, Kay Ristow, Thomas M Habermann, et al.
Leukemia & Lymphoma|February 20, 2014
Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphomaLuis F Porrata, Kay M Ristow, Thomas M Habermann, et al.
Leukemia & Lymphoma|June 24, 2008
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment GroupThomas E Witzig, Susan M Geyer, Paul J Kurtin, et al.
British Journal of Haematology|August 8, 2006
Absolute lymphocyte count predicts overall survival in follicular lymphomasMustaqeem Siddiqui, Kay Ristow, Svetomir N Markovic, et al.
Leukemia & Lymphoma|October 27, 2006
The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphomaIvana N M Micallef, Ellen D Remstein, Stephen M Ansell, et al.
Mayo Clinic Proceedings|February 13, 2004
Therapeutic options in patients with lymphoma and severe liver dysfunctionIrene M Ghobrial, Robert C Wolf, Denise L Pereira, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
British Journal of Haematology|February 25, 2012
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphomaLuis F Porrata, Kay Ristow, Thomas M Habermann, et al.
British Journal of Haematology|April 17, 2007
Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomasDeepti Behl, Kay Ristow, Svetomir N Markovic, et al.
American Journal of Hematology|March 16, 2010
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphomaPatrick B Johnston, David J Inwards, Joseph P Colgan, et al.
Ophthalmology|December 20, 2005
Natural killer/T-cell lymphoma with ocular and adnexal involvementJohn J Woog, Yoon Duck Kim, R Patrick Yeatts, et al.
Leukemia & Lymphoma|November 22, 2011
The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphomaRyan A Wilcox, Kay Ristow, Thomas M Habermann, et al.
Leukemia & Lymphoma|February 20, 2014
Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphomaLuis F Porrata, Kay M Ristow, Thomas M Habermann, et al.
Leukemia & Lymphoma|June 24, 2008
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment GroupThomas E Witzig, Susan M Geyer, Paul J Kurtin, et al.
British Journal of Haematology|August 8, 2006
Absolute lymphocyte count predicts overall survival in follicular lymphomasMustaqeem Siddiqui, Kay Ristow, Svetomir N Markovic, et al.
Leukemia & Lymphoma|October 27, 2006
The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphomaIvana N M Micallef, Ellen D Remstein, Stephen M Ansell, et al.
Mayo Clinic Proceedings|February 13, 2004
Therapeutic options in patients with lymphoma and severe liver dysfunctionIrene M Ghobrial, Robert C Wolf, Denise L Pereira, et al.
Pageof 4